Tenaya to Detail TN-401 Safety and Efficacy at 3E13 and 6E13 vg/kg Doses at ASGCT
Tenaya Therapeutics will present one-year cohort 1 and early cohort 2 safety, biopsy and efficacy data from its RIDGE-1 Phase 1b/2 TN-401 gene therapy at 3E13 and 6E13 vg/kg doses on May 15 at the ASGCT annual meeting. A webcast call will review these mid-stage results and guide TN-401’s development.
1. ASGCT Late-Breaking Presentation of RIDGE-1 Data
On May 15, Tenaya will deliver a late-breaking oral presentation of interim RIDGE-1 Phase 1b/2 trial data for TN-401 in adults with PKP2-associated ARVC. The presentation will feature one-year cohort 1 results and early cohort 2 safety, biopsy and efficacy findings at 3E13 and 6E13 vg/kg doses.
2. Webcast Conference Call Details
Tenaya management has scheduled a webcast conference call to discuss the ASGCT data and its implications for TN-401’s development. Call details and timing will be posted on the investor section of the company website ahead of the May 15 presentation.
3. Additional ASGCT Poster Sessions
Two poster presentations complement the oral session: one on parental perceptions of pediatric cardiomyopathy gene therapy (#1372) on May 12, and another on the development of TN-501 gene editing for PLN-R14del dilated cardiomyopathy (#3432) on May 14, both at ASGCT 2026.
4. TN-401 and RIDGE-1 Trial Overview
TN-401 is an AAV9-based gene replacement therapy targeting PKP2 mutations in arrhythmogenic right ventricular cardiomyopathy, holding Orphan Drug and Fast Track designations. The RIDGE-1 trial is a multi-center, open-label Phase 1b/2 dose-escalation study in the U.S. and U.K. evaluating safety, tolerability and preliminary efficacy.